Search

Your search keyword '"Mozer-Lisewska, I"' showing total 191 results

Search Constraints

Start Over You searched for: Author "Mozer-Lisewska, I" Remove constraint Author: "Mozer-Lisewska, I"
191 results on '"Mozer-Lisewska, I"'

Search Results

1. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

2. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

3. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study

4. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens

5. The extent of B‐cell activation and dysfunction preceding lymphoma development in HIV‐positive people†

6. Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort

7. The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study

8. Observational cohort study of rilpivirine (RPV) utilization in Europe

9. HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe

11. Gender differences in the use of cardiovascular interventions in HIV‐positive persons; the D:A:D Study

12. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

14. Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe

15. Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort

16. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens

17. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

18. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

21. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

25. Liver-related death among HIV/hepatitis C virus-co-infected individuals

26. Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression : A prospective cohort study

27. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study

28. Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study

29. Predictors of Hepatic Decompensation during Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir ± Ribavirin Treatment of Genotype 1 and 4 HCV Infected Patients (Real Life Amber Study)

30. Predictors of Fast Response to Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir ± Ribavirin in Real Life Amber Study in Genotype 1 and 4 HCV Infected Patients as a Rationale for Shortening of Treatment

36. SAT-252 - Predictors of Fast Response to Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir ± Ribavirin in Real Life Amber Study in Genotype 1 and 4 HCV Infected Patients as a Rationale for Shortening of Treatment

40. 462 HEPATITIS C VIRUS LOAD AND EXPRESSION OF A UNIQUE SUBSET OF CELLULAR GENES IN LYMPHOID CELLS DIFFERENTIATE NONRESPONDERS FROM RESPONDERS TO PEGYLATED INTERFERON ALPHA-RIBAVIRIN TREATME

44. Flow cytometric analysis of CD55 and CD59 expression on blood cells in paroxysmal nocturnal haemoglobinuria

Catalog

Books, media, physical & digital resources